ARANESP- darbepoetin alfa injection, solution 
ARANESP- darbepoetin alfa solution 
Amgen Inc



Aranesp® (Air-uh-nesp)

(darbepoetin alfa)

Read this Medication Guide:

This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Talk with your healthcare provider regularly about the use of Aranesp and ask if there is new information about Aranesp. 

What is the most important information I should know about Aranesp?

Aranesp may cause serious side effects that can lead to death, including:

For people with cancer: 

For all people who take Aranesp, including people with cancer or chronic kidney disease:

See “What are the possible side effects of Aranesp?” below for more information.

If you decide to take Aranesp, your healthcare provider should prescribe the smallest dose of Aranesp that is necessary to reduce your chance of needing red blood cell transfusions.

What is Aranesp?

Aranesp is a prescription medicine used to treat anemia. People with anemia have a lower-than-normal number of RBCs. Aranesp works like the human protein called erythropoietin to help your body make more RBCs. Aranesp is used to reduce or avoid the need for RBC transfusions.

Aranesp may be used to treat anemia if it is caused by:

If your hemoglobin level stays too high or if your hemoglobin goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take Aranesp, even if you do not have an increase in your hemoglobin level.

Aranesp should not be used for the treatment of anemia:

Aranesp has not been proven to improve the quality of life, fatigue, or well-being.

Who should not take Aranesp?

Do not take Aranesp if you:

What should I tell my healthcare provider before taking Aranesp?

Aranesp may not be right for you. Tell your healthcare provider about all your health conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of your medicines with you and show it to your healthcare provider when you get a new medicine.

How should I take Aranesp?

What are the possible side effects of Aranesp?

Aranesp may cause serious side effects.

The needle cover on the prefilled syringe contains latex. If you know you are allergic to latex, talk to your healthcare provider before using Aranesp.

Common side effects of Aranesp include:

These are not all of the possible side effects of Aranesp. Your healthcare provider can give you a more complete list. Tell your healthcare provider about any side effects that bother you or that do not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Aranesp?

Keep Aranesp and all medicines out of the reach of children.

General information about Aranesp

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Use Aranesp only for the condition for which it has been prescribed. Do not give Aranesp to other patients even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about Aranesp. If you would like more information about Aranesp, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Aranesp that is written for healthcare professionals. For more information, go to the following website: or call 1-800-77-AMGEN.

What are the ingredients in Aranesp?

Active Ingredient: darbepoetin alfa

Inactive Ingredients: polysorbate 80, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and sodium chloride in Water for Injection, USP.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 U.S.A.

Revised: 4/2017

© 2001-2017 Amgen Inc. All rights reserved.

1xxxxxx – v6                                                             PMV 5

Revised: 4/2017
Amgen Inc